Last $0.52 USD
Change Today +0.0097 / 1.90%
Volume 2.2K
TPI On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 12:36 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

tianyin pharmaceutical co in (TPI) Snapshot

Open
$0.51
Previous Close
$0.51
Day High
$0.52
Day Low
$0.51
52 Week High
03/6/14 - $1.37
52 Week Low
10/14/14 - $0.43
Market Cap
15.3M
Average Volume 10 Days
79.5K
EPS TTM
$0.18
Shares Outstanding
29.4M
EX-Date
05/11/10
P/E TM
2.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for TIANYIN PHARMACEUTICAL CO IN (TPI)

Related News

No related news articles were found.

tianyin pharmaceutical co in (TPI) Related Businessweek News

No Related Businessweek News Found

tianyin pharmaceutical co in (TPI) Details

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company, researches, manufactures, markets, and sells biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines, and other pharmaceuticals in the People’s Republic of China. It offers a portfolio of 58 products for use in the therapeutic areas of internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, and orthopedics. The company markets its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies. Tianyin Pharmaceutical Co., Inc. was founded in 1994 and is headquartered in Chengdu, the People’s Republic of China.

tianyin pharmaceutical co in (TPI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $100.0K
Chief Financial Officer, Chief Business & Dev...
Total Annual Compensation: $100.0K
Chief Operating Officer, Chief Advisor of Sal...
Total Annual Compensation: $80.0K
Vice President of Operations
Total Annual Compensation: $80.0K
Vice President of Marketing and Sales
Total Annual Compensation: $80.0K
Compensation as of Fiscal Year 2013.

tianyin pharmaceutical co in (TPI) Key Developments

Tianyin Pharmaceutical Receives Non-Compliance Notice From NYSE

On October 15, 2014, Tianyin Pharmaceutical Co., Inc. received a notice from the NYSE MKT Staff indicating that the Company is below certain of the continued listing standards of the NYSE MKT (the “Exchange”) as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing its Annual Report on Form 10-K for fiscal year ended June 30, 2014 beyond the extended filing due date of October 14, 2014. Currently the Company is working diligently with the auditor to finish the audit and complete the 2014 10-K, and expect to file the 2014 Form 10-K by October 29, 2014. Furthermore, on October 21, 2014, the company received another notice from the Exchange regarding its non-compliance with Section 803(B)(2)(a)(iii) of the NYSE MKT Company Guide indicating that the Company has failed to maintain at least one member of the Audit Committee who is financially sophisticated, due to the resignation of Mr. Bo Tan, who served as the Company's Independent Director and Chairman of Audit, Compensation and Nominating Committees until September 30, 2014. The Company is currently actively seeking candidates who are financially sophisticated to replace Mr. Tan to serve as Independent Director and Chairman of Audit, Compensation and Nominating Committees.

Tianyin Pharmaceutical Co., Inc. announced delayed annual 10-K filing

On 09/29/2014, Tianyin Pharmaceutical Co., Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Tianyin Pharmaceutical Co., Inc. Announces Progress Updates for TPI's Qionglai Facility

Tianyin Pharmaceutical Co., Inc. provided further updates regarding the Company's Qionglai Facility (QLF). A series of testing runs with individual production lines have been performed at QLF in July following the equipment installation. The specific products that were produced during these manufacturing testing runs included Qianlie Shule Capsules, Gingko Mihuan Oral Liquid, Xuelian Chongcao Oral Liquid, and Qiangli Pipa Oral Liquid. The testing runs have been completed successfully. These procedures of testing runs are essential for QLF GMP certification to be issued by the China Food & Drug Administration (the "CFDA"). The QLF facility is a combination of both pre-extraction plant (TCM) and formulation plant. The pre-extraction facility is designed to process and purify raw materials for TCMs using ethanol or distilled water precipitation, filtration, centrifugation, concentration and purification, which will be further processed for the production of modernized TCM products at the formulation facility where the final biopharmaceutical, TCM and generic products in the forms of oral liquid, granules, tablets, and capsules are produced.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPI:US $0.52 USD +0.0097

TPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TPI.
View Industry Companies
 

Industry Analysis

TPI

Industry Average

Valuation TPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 0.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIANYIN PHARMACEUTICAL CO IN, please visit www.tianyinpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.